

Caplin Point Laboratories Limited

Regd. office: Ashvich Tower, 3rd Floor, No.3, Developed Plots Industrial Estate, Perungudi, Chennai – 600096. Phone: +91 44 24968000 / +91 80127 72888 / +91 44 71148000

E-mail: info@caplinpoint.net / Website: www.caplinpoint.net CIN: L24231TN1990PLC019053

November 14, 2025

BSE Limited

Department of Corporate Relationship 1st Floor, New Trade Ring, Rotunda Building Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001

Scrip Code: 524742

National Stock Exchange of India Ltd.,

Department of Corporate Services Exchange Plaza, 5th Floor, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') -**Acquisition of land by Subsidiary**

Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, we would like to inform that the Company's step-down subsidiary, M/s. Triwin Pharma S.A DE C.V, Mexico had acquired land measuring approximately 5.5 acres located at Municipality of Capulhuac, District of Tenango Del Valle, State of Mexico for the purpose of setting up a manufacturing facility.

The details required under regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed as Annexure A.

Kindly take the same on record.

Thanking You,

Sincerely Yours For Caplin Point Laboratories Limited

Venkatram G **General Counsel & Company Secretary** Membership No. A23989

Encl: A/a

Caplin Point Laboratories Limited



Regd. office: Ashvich Tower, 3rd Floor, No.3, Developed Plots Industrial Estate, Perungudi, Chennai – 600096.
Phone: +91 44 24968000 / +91 80127 72888 / +91 44 71148000
E-mail: info@caplinpoint.net / Website: www.caplinpoint.net
CIN: L24231TN1990PLC019053

Annexure - A

Sr. No.	Particulars	Details
1	Existing capacity	Not applicable as the project pertains to a greenfield site.
2	Existing capacity utilization	Not applicable.
3	Proposed capacity addition	In the initial phase, the unit will have the facility to manufacture Suppositories, Topicals and other products. Initial capacity expected to be 50 million units per annum.
4	Period within which proposed capacity is to be added	Facility is targeted to be commissioned during FY 2027.
5	Investment required	Investment in land is USD 22,37,000 (INR 19.85 Crores) and the proposed investment in setting up the manufacturing facility is up to USD 15 million (INR 133 Crores)
6	Mode of financing	Internal accruals
7	Rationale	To enable the Company's expansion in Mexican market as well as harnessing the incentives in setting up local manufacturing in Mexico.

For Caplin Point Laboratories Limited

Venkatram G General Counsel & Company Secretary Membership No. A23989